Project

Horizon_HZNP-HZN-825-301

Ongoing - recruitment active ยท 2022 until 2025

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2022
End Date
2025
Financing
Others
Phase
II
Brief description/objective

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis